#London #United Kingdom #Matthew Mace #Precision Cardiovascular #Cardiac Health

Precision Cardiovascular Welcomes Matthew I. Mace to Board

Precision Cardiovascular (PCV), a frontrunner in innovative cardiac health technologies, has announced the addition of Matthew I. Mace, a distinguished Clinical Physiologist and strategic expert in medical technology, to its Board of Directors. This decision marks a pivotal moment for PCV as it gears up to enter clinical trials in 2026.

Background of Matthew Mace

Matthew Mace, holding a Bachelor of Science degree, brings over 15 years of unparalleled experience in both invasive and non-invasive cardiovascular medical devices. His career showcases a blend of academic prowess and practical achievement in the field, particularly in regulatory affairs and clinical development.

Leadership in Implantable Devices

Previously serving as the UK and Ireland Product Manager for Abbott, Matthew played a crucial role in pushing the commercial aspects of Cardiac Resynchronisation Therapy (CRT) devices. Under his guidance, the company launched the UK's first CardioMEMS HF monitoring sites, successfully capturing over 5% market share in the CRMs sector.

Innovation in Non-Invasive Technologies

As the Chief Scientific Officer and co-founder of Acorai, Matthew's leadership led to significant advancements, including the achievement of FDA Breakthrough designation for an advanced ML-driven intracardiac pressure reader. His contributions attracted over $17 million in funding and launched a global clinical trial involving 1,600 patients across six different nations.

Commercial Success at Circle Cardiovascular Imaging

In a strategic role at Circle Cardiovascular Imaging, Matthew steered worldwide marketing and sales efforts, achieving a remarkable transformation that resulted in doubling revenues to over $50 million annual recurring revenue within just 18 months.

Enhancing PCV's Leadership Team

Matthew's appointment comes at a crucial juncture for Precision Cardiovascular, as highlighted by the CEO, Mohamed Abou-Alam. "Matthew’s unique expertise in traditional cardiac devices coupled with his insight into AI-driven solutions will significantly advance our navigation through complex regulatory landscapes. This will be instrumental as we prepare for upcoming clinical trials, ensuring our innovations meet stringent safety and efficacy standards."

As PCV enhances its pre-clinical work for its cutting-edge minimally invasive hemodynamic monitoring solutions, Matthew's extensive regulatory experience is expected to smoothen the pathway to clinical trials, expected to commence in 2026. His insights into industry operations will aid in establishing robust quality systems within the organization, essential for any startup transitioning into a more extensive operational model.

The Future of Precision Cardiovascular

Precision Cardiovascular is dedicated to pioneering remote monitoring solutions for heart failure management, merging advanced sensor technologies with machine learning. Their current pipeline is investigational but is poised for future clinical application as the company pushes forward toward global commercialization.

In conclusion, with Matthew I. Mace on board, PCV is optimistic about augmenting its capabilities in cardiac care through innovative medical solutions that not only aim for scientific breakthroughs but also focus on real-world clinical benefits for patients worldwide. As they prepare for the next steps in the clinical development of their flagship cardiac sensor technology, the strategic vision and implementation of Matthew Mace will be invaluable.

For further information, media inquiries can be directed to Precision Cardiovascular through their official contact email.